|
(Health-NewsWire.Net, December 23, 2019 ) Market Overview
• Nephrology is the medical specialty which focuses on the treatment of kidney conditions and abnormalities. Urologist focuses on diseases and conditions that affect the male and female urinary tract.
• The urinary tract includes the kidneys, and also other parts such as the ureters, bladder, and urethra. The urologist also works with the male reproductive organs, such as the penis, testes, and prostate.
• Various tests are performed to assess the function of kidneys. These tests are typically performed on either a blood or urine sample.
• The blood test includes; Glomerular filtration rate (GFR), Serum creatinine, and Blood urea nitrogen (BUN). The Urine tests include; Urinalysis, Albumin/creatinine ratio (ACR), Creatinine clearance.
• The global nephrology and urology devices market was worth YY billion in 2018 and is forecasted to reach YY billion by 2026, at a CAGR of YY% during the forecast period.
Download free sample: https://www.datamintelligence.com/download-sample/nephrology-and-urology-devices-market
Market Outlook
• The rising prevalence of kidney disorder is one of the factors fueling the global nephrology and urology devices market.
• For instance, according to the National Kidney Foundation, 10% of the population worldwide is affected by chronic kidney disease (CKD).
• According to the Centers for Disease Control and Prevention (CDC) 30 million people or 15% of US adults are estimated to have CKD. About 40% of people with diabetes have CKD in U.S. 1 in 7 U.S. adults has chronic kidney disease. The most common causes of kidney failure are diabetes and high blood pressure and accounting for about 72% of new cases.
• According to the American Society of Nephrology, in 2015, there are 3,026,595 patients with chronic kidney disease in California and 58,999 patients with dialysis.
Market Segmentation
• Based on the type the global market for nephrology and urology devices is broadly segmented as by dialysis devices, urinary stone treatment devices, urinary incontinence & pelvic organ prolapse devices, benign prostatic hyperplasia (BPH) treatment devices, and endoscopy devices.
• Currently, dialysis devices are the dominant segment, and it accounts for approximately YY% of the market, due to the increasing clinical trial, regulatory approval and strategic alliance between companies for dialysis devices.
• For instance, in January 2019, AWAK Technologies, a pioneering medical technology company focused on dialysis using regeneration technology for end-stage renal disease, have received US Food and Drug Administration (FDA) approval for its AWAK Peritoneal Dialysis device, a wearable and ultra-portable PD system that incorporates AWAK’s patented sorbent technology.
• In October 2018, AWAK Technologies has completed Phase I study investigating the safety of dialysis treatment for patients with End Stage Renal Disease (ESRD) led by the Singapore General Hospital (SGH).
• In November 2015, Debiotech and Fresenius Medical underwent in a partnership agreement to develop home-usable peritoneal dialysis technologies.
Geographical Analysis
• The global nephrology and urology devices market is segmented into North America, Europe, Asia Pacific, South America, and ROW.
• North America is dominating the global nephrology and urology devices market, due to the regulatory approval, and strategic agreement between companies, which is fueling the market growth.
• For instance, in June 2018, the U.S. Food and Drug Administration (FDA) has approved for marketing the Ellipsys Vascular Access System and the everlinQ endoAVF System to make what’s called an arteriovenous (AV) fistula for patients with hemodialysis.
• In August 2016, Baxter signed a four-year agreement with Satellite Healthcare, a non-profit organization that provides kidney dialysis and other related services.
• Baxter’s technology in peritoneal dialysis, hemodialysis, and continuous renal replacement therapy have been incorporated into Satellite Healthcare’s service offered to 7,000 patients in the U.S.
Competitive Trends
• The strategic alliance between companies is one of the key factor driving the global nephrology and urology devices market.
• For instance, in December 2018, AstraZeneca have partnered with FibroGen Medical Technology Development Co., and received marketing authorisation from the National Medical Products Administration (NMPA) for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and new oral treatment for patients with anaemia caused by chronic kidney disease (CKD) that are on dialysis.
• In July 2018, Becton, Dickinson and Company, a leading global medical technology company, have acquired TVA Medical, Inc., a company that develops minimally invasive vascular access solutions for patients with chronic kidney disease requiring hemodialysis.
• In August 2017, Fresenius Medical Care, the world’s largest provider of dialysis products and services, has acquired NxStage Medical, Inc., a U.S.-based medical technology and services company.
• The acquisition enables Fresenius Medical Care to further leverage its manufacturing, supply chain and marketing competencies across the dialysis products, services, and care coordination businesses in a less labor- and capital-intensive care setting.
View full report: https://www.datamintelligence.com/research-report/nephrology-and-urology-devices-market
Enquiry before buying: https://www.datamintelligence.com/enquiry/nephrology-and-urology-devices-market
About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information:
Sai Kiran
Sales Manager at DataM Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
